BioLineRx (BLRX) Gains from Investment Securities (2014 - 2025)

BioLineRx's Gains from Investment Securities history runs 12 years deep, the most recent figure standing at -$1.1 million for Q4 2025.

• In Q4 2025, Gains from Investment Securities rose 80.46% year-over-year to -$1.1 million; the TTM figure through Dec 2025 stood at -$8.6 million (up 54.66% YoY), while the FY2025 annual figure was -$8.6 million, up 54.66% from the prior year.
• Gains from Investment Securities was -$1.1 million for Q4 2025 at BioLineRx, up from -$1.1 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $7.8 million in Q2 2023 to a low of -$8.4 million in Q2 2024.
• Historically, Gains from Investment Securities has averaged -$1.0 million across 5 years, with a median of -$1.1 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities soared 1966.75% in 2023, then plunged 246.18% in 2024.
• A 5-year view of Gains from Investment Securities shows it stood at -$2.2 million in 2021, then slumped by 69.31% to -$3.6 million in 2022, then grew by 20.1% to -$2.9 million in 2023, then sank by 85.24% to -$5.4 million in 2024, then jumped by 80.46% to -$1.1 million in 2025.
• The last three Gains from Investment Securities figures came in at -$1.1 million (Q4 2025), -$1.1 million (Q3 2025), and $1.9 million (Q2 2025), per Business Quant data.